Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Exousia Bio (LMMY) Operating Expenses (2022 - 2025)

Lamy (LMMY) has disclosed Operating Expenses for 4 consecutive years, with $174897.0 as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 2405.33% to $174897.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $226787.0 through Nov 2025, up 863.41% year-over-year, with the annual reading at $31843.0 for FY2025, 13.42% up from the prior year.
  • Operating Expenses hit $174897.0 in Q4 2025 for Lamy, up from $31814.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $174897.0 in Q4 2025 to a low of -$3751.0 in Q2 2025.
  • Historically, Operating Expenses has averaged $23311.2 across 4 years, with a median of $8551.0 in 2022.
  • Biggest YoY gain for Operating Expenses was 2405.33% in 2025; the steepest drop was 1545.18% in 2025.
  • Year by year, Operating Expenses stood at $8407.0 in 2022, then decreased by 11.41% to $7448.0 in 2023, then fell by 6.27% to $6981.0 in 2024, then soared by 2405.33% to $174897.0 in 2025.
  • Business Quant data shows Operating Expenses for LMMY at $174897.0 in Q4 2025, $31814.0 in Q3 2025, and -$3751.0 in Q2 2025.